QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
The American Cancer Society annually estimates the number of new cancer cases and deaths in the United States. It compiles data on cancer occurrence and outcomes. In 2025, over two million cancer cases and six hundred thousand cancer deaths are…
This large U.S.-based cohort study examined how county-level prostate-specific antigen (PSA) screening prevalence is associated with prostate cancer outcomes among over 814,000 men diagnosed between 2000 and 2015. Key findings include: Higher PSA screening prevalence was linked to: • Lower…
Multi-parametric MRI (mpMRI) is a key imaging tool for identifying clinically significant prostate cancer (defined as Gleason score≥7). However, its sensitivity and specificity are not perfect. Prostate cancer is highly heritable, and polygenic risk scores (PRS) based on germline…
This study looked at how well a newer type of imaging called PSMA-PET/CT works in detecting cancer in patients with high-risk, hormone-sensitive prostate cancer. These patients were similar to those included in the large EMBARK trial, which tested the drug…
This study focused on the often- overlooked health risks that men face when they carry inherited mutations in the BRCA1 and BRCA2 genes. While these genetic variants are commonly associated with a higher risk of breast and ovarian cancer in…
A long-term study involving over 19,000 men from Sweden and the U.S. investigated how genetic risk and lifestyle choices impact early prostate cancer deaths. The research, conducted from 1991 to 2019, found that men with higher genetic risk—determined by a…
A recent international study examined the ability of an artificial intelligence (AI) system to detect clinically significant prostate cancer on MRI scans, comparing it to that of experienced radiologists using the Prostate Imaging- Reporting and Data System version 2.1 (PI-RADS…
• Newsweek/Showmark, “Your America’s Best Prostate Cancer Surgeons 2025.” • Chicago Magazine, “Top Doctors in America Recognized for Excellence 2025” • Nominated for Who’s Who in America 2025 • ScholarGPS celebrates highly ranked scholars for their exceptional performance in various…
Thirty years ago, at age 64, through PSA testing, Eugene (Gene) Golub received a diagnosis of prostate cancer. He consulted Dr. Catalona, who then worked at Washington University in St. Louis and successfully treated him. Years later, they reconnected at…
Multiparametric Magnetic Resonance Imaging (mpMRI) improves the pathway for diagnosing prostate cancer and detecting the clinically significant form of this disease. Moreover, some with a negative MRI scan can avoid prostate biopsy. In routine clinical practice, the PI-RADS scoring system…
"*" indicates required fields
